Shares of Madrigal Pharmaceuticals (NASDAQ: MDGL) were soaring 15.2% higher as of 11:05 a.m. ET on Wednesday. The big gain ...

Three months ago, in its third-quarter report, Madrigal pointed out that it achieved a key goal early by gaining 80% coverage ...

B. Riley upgraded shares of Madrigal Pharmaceuticals (NASDAQ:MDGL – Free Report) from a hold rating to a strong-buy rating in a research note issued to investors on Thursday morning, Marketbeat ...

BofA raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $239 from $154 and keeps an Underperform rating on ...

Madrigal Pharmaceuticals MDGL reported fourth-quarter 2024 loss of $2.71 per share, narrower than the Zacks Consensus ...

Madrigal Pharmaceuticals' Rezdiffra had a strong launch with $103.3M in Q4 sales and solid liquidity. See why I have a ...

Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) had its target price increased by analysts at HC Wainwright from $400.00 to $405.00 in a research note issued to investors on Thursday ...

Bill Sibold, Madrigal Pharmaceuticals CEO , joins 'Fast Money' to talk quarterly results.

B. Riley upgraded Madrigal Pharmaceuticals (MDGL) to Buy from Neutral with a price target of $422, up from $236. The firm notes the erosion of ...

Madrigal Pharmaceuticals, Inc.'s Rezdiffra, the first approved drug for MASH, showed strong sales growth, with Q4 net sales ...

Reports Q4 revenue $103.3M, consensus $97.81M. Bill Sibold, Chief Executive Officer of Madrigal, stated, “Looking back on 2024, I’m incredibly ...

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) reported two-year results from the open-label compensated MASH cirrhosis (F4c) ...